CJC-1295 Dosage Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Medical disclaimer: This article is educational and is not medical advice, nor a set of self-administration instructions. CJC-1295 is not an FDA-approved drug. Any dosing described here reflects published research and compounded, physician-directed protocols — it is not a prescription and should never be undertaken without a qualified physician’s supervision, lab monitoring, and an individualized plan. Do not obtain or self-inject research peptides.

Quick CJC-1295 Dosing Summary

CJC-1295 comes in two very different forms, and the dose depends entirely on which one you have. CJC-1295 with DAC (a long-acting, albumin-binding version with a half-life of roughly 6-8 days) is typically dosed at 1-2 mg once or twice weekly. CJC-1295 without DAC — also called Modified GRF 1-29 (Mod GRF 1-29), with a half-life near 30 minutes — is typically dosed at 100-300 mcg, one to three times daily, usually before bed and on an empty stomach. The two are not interchangeable.

The single most common way CJC-1295 is used clinically is the no-DAC form stacked with ipamorelin. If that is the protocol you are exploring, read our dedicated CJC-1295 / Ipamorelin dosage guide for the combined protocol. This page covers CJC-1295 on its own, in both forms.

Schedule a Peptide Therapy Consultation →

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It works upstream in the body’s own growth hormone (GH) axis: rather than supplying GH directly, it binds the GHRH receptor on the pituitary’s somatotroph cells and prompts the pituitary to release its own stored GH. Because the signal still passes through the pituitary and remains subject to the body’s natural brake — the hormone somatostatin — CJC-1295 augments physiological GH release rather than overriding it.

The molecule is built on the biologically active 1-29 fragment of native GHRH. Four amino-acid substitutions are engineered into that backbone to resist enzymatic breakdown (particularly by the enzyme DPP-IV) and to prevent the peptide from being cleared as quickly as natural GHRH. That modified 29-amino-acid peptide is the “no-DAC” form, and it is why the no-DAC version is also called Modified GRF 1-29.

The critical distinction: DAC vs no-DAC

The letters “DAC” stand for Drug Affinity Complex. In the DAC version, a small chemical linker (a maleimidopropionyl group) is attached to the peptide. After subcutaneous injection, that linker forms a covalent bond with albumin — the most abundant protein in your bloodstream. Bound to albumin, the peptide is shielded from clearance and circulates for days rather than minutes. This is the entire reason CJC-1295 with DAC can be dosed weekly while no-DAC must be dosed daily.

• CJC-1295 with DAC — long-acting “bleed” of GHRH signal; sustained elevation of GH and IGF-1 over several days; dosed weekly or twice weekly.
• CJC-1295 without DAC (Mod GRF 1-29) — short, sharp pulse of GHRH signal that clears within an hour; mimics the body’s natural pulsatile pattern; dosed daily, usually at night.

Why the form dictates everything

Every downstream decision — dose size, injection frequency, timing, whether to stack it, how you cycle it, and what side effects to watch for — flows from which form you have. Confusing the two is the most common and most consequential error people make with this peptide. Throughout this guide we label every protocol by form.

Common vial sizes

CJC-1295 is supplied as a lyophilized (freeze-dried) white powder in sealed vials, most commonly 2 mg or 5 mg per vial. The powder must be reconstituted with bacteriostatic water before use. Note that a 2 mg or 5 mg vial does not tell you the form — a vial can be either DAC or no-DAC at the same milligram weight, so the label and the compounding pharmacy’s documentation must specify which.

A brief history of CJC-1295’s development

CJC-1295 was developed in the early 2000s by ConjuChem, a Canadian biotechnology company, as a candidate long-acting GHRH therapeutic. The “CJC” designation and the Drug Affinity Complex technology were the company’s approach to solving GHRH’s central practical problem: native GHRH is destroyed within minutes, making it impractical as a drug. By covalently tethering the peptide to albumin, ConjuChem extended activity from minutes to days. The compound advanced through early-phase human testing (the Teichman trials discussed below) but did not proceed to approval, and it subsequently migrated into the compounding and research-peptide space where it exists today. Understanding this history matters because it explains why the human evidence base is small and dated, and why the no-DAC form — never a formal drug candidate in the same way — rests largely on GHRH-class pharmacology rather than dedicated trials.

What Does CJC-1295 Do? Researched Benefits and Mechanism

CJC-1295 does not act on muscle, fat, or skin directly. Everything it is studied for is downstream of one event: a rise in the body’s own growth hormone and, consequently, in insulin-like growth factor 1 (IGF-1), the liver-derived hormone that mediates most of GH’s tissue effects. The benefits below should be read as what an optimized GH/IGF-1 axis is associated with — framed as “studied for,” not guaranteed outcomes — with honest acknowledgment that dedicated CJC-1295 outcome trials are limited.

How the GH/IGF-1 axis works

The hypothalamus releases GHRH (stimulating) and somatostatin (inhibiting) in an alternating rhythm. When GHRH wins out, the pituitary’s somatotrophs release a pulse of GH; between pulses, somatostatin dominates and GH falls to near zero. GH then acts on the liver and peripheral tissues to raise IGF-1, which does much of the anabolic and reparative work. CJC-1295 plugs into the top of this cascade as a GHRH signal, which is why it is called a “secretagogue-adjacent” or GHRH-analog approach: it asks the body to make more of its own GH rather than injecting GH itself. That is also why its effect remains capped by somatostatin — a built-in safety feature that exogenous HGH lacks.

Body composition and lean mass

GH and IGF-1 are associated with supporting lean body mass and with lipolysis (fat breakdown), particularly of visceral fat. This is the most-cited reason patients explore GHRH-analog therapy alongside resistance training and a controlled diet. The strongest human data for GHRH-analog-driven visceral-fat reduction actually comes from tesamorelin (an FDA-approved GHRH analog), which lends biological plausibility to the class, though it does not prove equivalent results for CJC-1295 specifically.

Sleep and recovery

Because the largest natural GH pulse occurs in early deep sleep, and because many users take the no-DAC form at bedtime, improved sleep depth and next-day recovery are among the most commonly reported subjective benefits. This dovetails with GH’s established role in tissue repair.

Skin, connective tissue, and healthy aging

GH/IGF-1 signaling supports collagen synthesis and connective-tissue turnover, which is the rationale behind interest in skin quality, joint comfort, and general “vitality” markers as the axis declines with age. Evidence here is largely mechanistic and anecdotal rather than from large controlled trials, and it should be presented to patients that way.

Bone and metabolic signals

Over longer periods, GH/IGF-1 activity influences bone remodeling and metabolic rate. These are slow-moving effects and are not a reason to expect rapid change; they are part of why monitoring (including glucose, since GH can reduce insulin sensitivity) is built into a supervised protocol.

What the evidence does and does not show

The honest summary: human trials confirm that CJC-1295 with DAC reliably raises GH and IGF-1 for days (Teichman 2006) and preserves natural GH pulsatility (Ionescu & Frohman 2006). What those trials did not establish is long-term efficacy for body composition, anti-aging, athletic performance, or safety over months to years — nor did they study the daily no-DAC protocol most clinics use. CJC-1295 is best framed as a mechanistically sound, early-evidence peptide, not a proven therapy.

CJC-1295 Dosing Protocols Based on Clinical Research

The published human data on CJC-1295 comes almost entirely from the DAC form, studied in a small Phase 1 program in the mid-2000s. The no-DAC/Mod GRF 1-29 dosing that dominates clinical peptide practice today is extrapolated from GHRH pharmacology and clinical experience rather than large trials. We separate the two below, and we flag where evidence is strong versus where it is inferred.

Standard ranges by form

A widely used dosing convention for the no-DAC form is the “1 mcg per kg of body weight” saturation dose — roughly 100 mcg for most adults — because studies of GHRH analogs suggest the pituitary GH response tends to plateau near that amount per pulse. Dosing well above saturation increases cost and side-effect risk without a proportional GH benefit, which is why more-frequent smaller doses (rather than one large dose) is the typical strategy for the no-DAC form.

Beginners are generally started at the low end of the range for a given form and titrated upward only if labs and tolerance support it. Starting low serves two purposes: it lets the clinician see how an individual’s axis responds before committing to a higher exposure, and it minimizes the early water retention and tingling that tend to accompany a rapid rise in GH/IGF-1. For the no-DAC form, a common conservative entry point is a single 100 mcg pre-bed dose for the first week or two before adding a second daily dose. For the DAC form, a single 1 mg weekly injection is a typical starting point, with the second weekly dose or a step to 2 mg reserved for later, lab-guided adjustment.

It is worth restating that these ranges are population conventions, not personalized prescriptions. Body weight, baseline IGF-1, age, sex, training status, and goals all shift the appropriate dose, and two people on “the same” protocol can land in very different places on their lab work. This is a core reason the peptide belongs in a monitored program rather than a fixed, one-size-fits-all regimen.

Research-based protocols

No-DAC / Mod GRF 1-29 (most common clinical use): 100-300 mcg subcutaneously, once to three times daily, timed to the body’s natural GH windows — most importantly right before sleep, and optionally in the morning fasted and/or pre-workout. It is almost always paired with a growth-hormone secretagogue such as ipamorelin, because the GHRH “amplifier” (CJC no-DAC) and the ghrelin-receptor “trigger” (ipamorelin) act on two different pathways and produce a larger, cleaner GH pulse together than either alone. See the combined CJC-1295 / Ipamorelin protocol and the CJC-1295 / Ipamorelin therapy page for that stack.

With DAC (long-acting): 1-2 mg once or twice weekly. Because a single dose keeps GHRH tone elevated for the better part of a week, DAC protocols favor a fixed weekly (or twice-weekly) injection rather than daily dosing. The trade-off — discussed in the timing section below — is that DAC blunts the natural nighttime pulse pattern in exchange for convenience.

Clinical trial data

The pivotal human evidence is the Phase 1 program by Teichman and colleagues (2006), published in the Journal of Clinical Endocrinology & Metabolism. Two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults tested single subcutaneous doses of CJC-1295 with DAC (1-30 mcg/kg) and repeated weekly/biweekly dosing. Key findings:

• Half-life of 5.8-8.1 days for the DAC form — the empirical basis for weekly dosing.
• A single injection raised mean GH 2- to 10-fold for 6 or more days, dose-dependently.
• Mean IGF-1 rose 1.5- to 3-fold for 9-11 days after one dose; with repeated dosing, IGF-1 stayed above baseline for up to 28 days (a cumulative effect).
• The DAC form was reported safe and generally well tolerated in this small, short-term study.

A companion 2006 study by Ionescu and Frohman addressed a central mechanistic worry: does continuous GHRH stimulation flatten the natural GH rhythm? They found that pulsatile GH secretion persisted during continuous stimulation by CJC-1295 — the analog raised trough and mean GH and boosted IGF-1 while GH pulses were preserved, because endogenous somatostatin continues to gate release. In plain terms: CJC-1295 amplifies the body’s GH pulses rather than replacing them.

Two honest caveats. First, these trials were small, short, and conducted in healthy volunteers — they were not designed to prove long-term efficacy or safety for anti-aging, body-composition, or performance uses. Second, essentially all of the direct human data is on the DAC form; the daily no-DAC/Mod GRF 1-29 protocols used in clinics today are extrapolated from GHRH pharmacology and clinical experience, not from large randomized trials.

How to Reconstitute CJC-1295

Reconstitution means dissolving the freeze-dried peptide powder in bacteriostatic water so it can be drawn into a syringe and dosed accurately. In a physician-directed program this is typically prepared or taught by the clinic or compounding pharmacy. The steps below explain the process and the math so you can understand and verify a prescribed dose — not so you can source and mix peptide yourself.

Step-by-step reconstitution

1. Gather supplies: the CJC-1295 vial, bacteriostatic water (0.9% benzyl-alcohol preserved), alcohol swabs, a reconstitution syringe, U-100 insulin syringes for dosing, and a sharps container.
2. Sanitize: swab the rubber stopper of both the peptide vial and the bacteriostatic-water vial with alcohol and let them dry.
3. Draw the diluent: withdraw your chosen volume of bacteriostatic water (see the chart below — commonly 1-2 mL).
4. Add slowly: insert the needle at an angle and let the water run down the inside wall of the vial onto the powder. Do not squirt it forcefully onto the pellet.
5. Do not shake: gently swirl or roll the vial until the powder fully dissolves into a clear solution. Shaking can damage the peptide.
6. Store: refrigerate the reconstituted vial (about 2-8°C). Once mixed, most compounded peptide is used within roughly 3-4 weeks; follow your pharmacy’s specific dating.
7. Inspect before each use: the solution should be clear and particle-free. Discard if cloudy or discolored.

Dosing calculation examples (with syringe-unit math)

The math depends on concentration = total micrograms in the vial ÷ milliliters of water added. On a U-100 insulin syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. Once you know micrograms per mL, you can convert any dose to syringe units.

Worked example (no-DAC): a 5 mg vial reconstituted with 2 mL of bacteriostatic water = 2,500 mcg/mL. A 100 mcg dose = 100 ÷ 2,500 = 0.04 mL = 4 units on a U-100 syringe. A 250 mcg dose = 0.10 mL = 10 units.

Worked example (DAC): a 5 mg vial reconstituted with 2.5 mL = 2,000 mcg/mL. A 1 mg (1,000 mcg) weekly dose = 1,000 ÷ 2,000 = 0.5 mL = 50 units.

Always double-check concentration whenever a new vial is mixed at a different water volume, and confirm your syringe is truly U-100 (some are U-40 or U-50, which changes the unit-to-mL relationship).

CJC-1295 Administration Guide

Both forms are given by subcutaneous injection — into the fat layer just under the skin, not into muscle or vein. The technique is the same as an insulin injection.

Injection site selection

• Abdomen — the most common site; stay at least 2 inches (about two finger-widths) away from the navel.
• Upper outer thigh — the fleshier front-outer portion.
• Love handles / flank — the fatty area above the hip.
• Back of the upper arm — where enough subcutaneous fat is present.

Rotate sites with each injection to avoid local irritation, lipohypertrophy (fatty lumps), and bruising. Keep a simple rotation log if you are dosing daily.

Subcutaneous injection technique

1. Wash hands and swab the chosen site with alcohol; let it dry.
2. Gently pinch a fold of skin and fat.
3. Insert the short insulin needle at 45-90° into the fold.
4. Depress the plunger slowly and steadily to deliver the dose.
5. Withdraw the needle, release the pinch, and apply light pressure with a clean swab (do not rub).
6. Dispose of the needle immediately in a sharps container — never recap or reuse.

Because CJC-1295 doses are small volumes (often well under 0.3 mL), discomfort is usually minimal. Mild transient redness or a small welt at the site is common and typically resolves quickly.

Choosing the right syringe

Dosing is done with a U-100 insulin syringe (typically 0.3 mL / 30-unit or 0.5 mL / 50-unit barrels, with a short 29-31 gauge needle). The small barrel matters because CJC-1295 doses are tiny, and a 0.3 mL syringe lets you read units precisely — trying to measure 4 units in a large 1 mL syringe invites error. Confirm the syringe is genuinely U-100; a U-40 syringe would make you draw 2.5× the intended volume for the same “unit” reading. Use a fresh sterile syringe for every injection.

Storing and Handling CJC-1295

Peptides are fragile. Improper storage is one of the most common reasons a protocol underperforms — a degraded peptide simply won’t raise GH, no matter how carefully you dose it.

Before reconstitution

Lyophilized (freeze-dried) CJC-1295 powder is relatively stable and is generally kept refrigerated. For longer holding, many pharmacies store unreconstituted vials frozen. Keep vials sealed, dry, and away from light until you are ready to mix.

After reconstitution

Once mixed with bacteriostatic water, the solution must be refrigerated (about 2-8°C) and is typically used within a few weeks (commonly cited as roughly 3-4 weeks; follow your pharmacy’s specific dating). Do not freeze a reconstituted vial. Discard any solution that becomes cloudy, discolored, or shows particles.

Bacteriostatic vs sterile water

Bacteriostatic water contains 0.9% benzyl alcohol, which suppresses microbial growth and is why a multi-dose vial can be used over several weeks. Plain sterile water lacks that preservative and is only appropriate for single use. For a multi-dose peptide vial, bacteriostatic water is the standard diluent.

Travel and light exposure

Keep reconstituted vials cold in transit (an insulated pouch with a cold pack) and minimize time at room temperature and in direct light. Brief room-temperature exposure while dosing is fine, but the vial should return to the refrigerator promptly.

Optimal Timing for CJC-1295 Administration

Timing is where the two forms diverge most sharply, because it is driven by half-life.

Why no-DAC is dosed at night and fasted

The body’s largest natural GH pulse happens during early deep (slow-wave) sleep. Because Mod GRF 1-29 acts for only about 30 minutes, dosing it right before bed stacks a GHRH amplifier directly on top of that natural nocturnal pulse — the highest-yield window. Many protocols add a fasted morning and/or pre-workout dose to catch additional pulse windows.

The “empty stomach” rule matters because a meal — particularly one containing carbohydrates or fat — raises insulin and free fatty acids, both of which blunt the pituitary’s GH response. The practical convention is to inject no-DAC forms with at least 2-3 hours since the last meal and, ideally, no food for 20-30 minutes afterward, so the induced GH pulse isn’t suppressed.

Why DAC is dosed weekly (and timing matters less)

With DAC, the peptide keeps GHRH tone elevated for days, so a single injection’s clock hour is far less important — there is no discrete pulse to align with a meal or with sleep. The trade-off is that this “always-on” GHRH signal, while it preserves some pulsatility, produces a flatter, more continuous elevation than the sharp nightly spikes of the no-DAC form. For that reason many clinicians actually prefer the no-DAC + ipamorelin approach for a more physiological pattern, reserving DAC for patients who prioritize convenience and adherence.

Timing summary

CJC-1295 Cycle Length and Protocol Duration

CJC-1295 is generally used in cycles rather than continuously, both to gauge response and to reduce the theoretical risk of receptor desensitization from unrelenting stimulation.

• Typical cycle: 8-12 weeks of consistent dosing, followed by a planned break.
• Break: commonly 4 or more weeks off (or a “on 5 days / off 2 days” weekly pattern for no-DAC daily protocols) to let the axis reset.
• Evaluation: IGF-1 and clinical response are re-checked before deciding whether to repeat a cycle.

Because the DAC form drives such a durable IGF-1 elevation (weeks after the last dose in the Teichman data), clinicians tend to be more conservative with continuous DAC use and lean on lab monitoring to keep IGF-1 within an age-appropriate physiological range rather than pushing it high. There is no established “correct” lifetime duration — this is an off-label, individualized, physician-directed decision.

CJC-1295 Safety Profile and Potential Side Effects

Reported side effects are mostly mild and often related to the injection itself or to transient shifts in fluid and GH/IGF-1 levels. However, long-term safety data in humans is limited, and the following should be interpreted with that caveat.

Common side effects

• Injection-site reactions — redness, itching, a small welt, or bruising (the most frequently reported effect).
• Facial flushing or a warm sensation shortly after dosing.
• Water retention / mild edema, puffiness, or a bloated feeling.
• Tingling or numbness in the hands; occasionally carpal-tunnel-type symptoms at higher GH exposure.
• Headache, lightheadedness, or fatigue.
• Transient hunger changes or, with some GH-axis peptides, altered appetite.
• Reactive drowsiness after a pre-bed dose (which some users find desirable).

Contraindications and cautions

• Active or prior cancer — because GH/IGF-1 are growth-promoting, CJC-1295 is generally avoided in anyone with active malignancy or a significant cancer history until cleared by an oncologist.
• Pregnancy and breastfeeding — not to be used.
• Diabetes or insulin resistance — GH can raise blood glucose and reduce insulin sensitivity; requires careful glucose monitoring.
• Uncontrolled thyroid disease, severe illness, or proliferative retinopathy — evaluate before use.
• Children/adolescents — not appropriate outside of a formal medical indication and specialist care.

Drug interactions

• Insulin and oral hypoglycemics — GH elevation can raise glucose and may require dose adjustments.
• Corticosteroids (glucocorticoids) — can blunt the GH response to GHRH.
• Somatostatin analogs (e.g., octreotide) — directly oppose GHRH signaling.
• Thyroid hormone and sex steroids — modulate the GH/IGF-1 axis and can change the response.

Elevating IGF-1 chronically and substantially above the normal range is the central theoretical safety concern (relevant to insulin resistance and cell-proliferation risk). This is precisely why physician oversight with periodic IGF-1 testing is non-negotiable.

Two form-specific safety nuances are worth noting. The DAC form carries a somewhat higher water-retention and sustained-IGF-1 profile precisely because its effect lasts for days — there is no nightly return to baseline, so any excess accumulates over the week. The no-DAC form, by returning to baseline between doses, tends to produce a gentler side-effect profile but demands consistent daily technique to be effective. Neither form has robust long-term human safety data, so “well tolerated in short studies” should not be over-read as “proven safe for years of use.” Reporting new or worsening symptoms promptly, and treating lab work as the objective referee, is the practical safeguard.

Combining CJC-1295 with Other Peptides and Therapies

The defining feature of CJC-1295 in practice is that it is rarely used alone. Its natural partner is a growth-hormone secretagogue (ghrelin-receptor agonist) such as ipamorelin. The two act on different receptors and are synergistic: CJC-1295 (GHRH pathway) increases the amount of GH available to release, while ipamorelin (GHSR pathway) triggers a clean pulse and partially suppresses somatostatin — the brake. Together they produce a larger, more physiological GH pulse than either alone.

Related BHRC therapy pages: the CJC-1295 / Ipamorelin combination and Tesamorelin. For a deeper dive on the combined protocol, see our CJC-1295 / Ipamorelin dosage guide and the sibling Ipamorelin dosage guide.

CJC-1295 vs sermorelin

Because both are GHRH analogs, patients frequently ask how CJC-1295 differs from sermorelin. Sermorelin is native GHRH (1-29) — the closest possible synthetic copy of the body’s own signal, with a very short half-life (~10-20 min) and a naturally pulsatile effect. CJC-1295 is the same fragment engineered for stability: the no-DAC form resists breakdown (giving a slightly longer, cleaner pulse than sermorelin), and the DAC form adds albumin binding for a multi-day half-life.

The practical takeaway: sermorelin and CJC no-DAC both aim to reproduce the body’s natural rhythm (sermorelin with the most authentic signal, CJC no-DAC with a bit more stability), while CJC with DAC trades that rhythm for weekly convenience. Which is “better” depends on your goals, adherence, and how your clinician wants to monitor IGF-1.

Schedule a Peptide Therapy Consultation →

Who Should Consider CJC-1295 Therapy?

In a medically supervised setting, CJC-1295 (typically no-DAC with ipamorelin) is explored by adults who have documented, age-related decline in the GH/IGF-1 axis or symptoms consistent with it and who want to support GH levels physiologically rather than with exogenous HGH. Commonly cited goals — framed honestly as studied for, not guaranteed — include:

• Support of lean body mass and body composition alongside diet and training.
• Sleep quality (many report deeper sleep from a pre-bed GHRH pulse).
• Recovery, connective-tissue support, and general vitality.
• Skin quality and the subjective markers people associate with GH optimization.

It is not appropriate for anyone with active cancer, during pregnancy or breastfeeding, for children outside a formal indication, or for competitive athletes subject to anti-doping rules (see the legal section). Candidacy is decided by a physician after history, exam, and baseline labs — not by a symptom checklist.

A good candidacy conversation also covers realistic expectations and commitment. The no-DAC protocol requires daily, well-timed subcutaneous injections and dietary discipline around the fasted dosing window; someone unlikely to sustain that may be better served by the once-weekly DAC form or a different approach entirely. Conversely, a patient who wants the most physiological GH pattern and is comfortable with daily dosing is often steered toward the no-DAC-plus-ipamorelin stack. The “right” choice is as much about lifestyle and adherence as it is about pharmacology, which is why an individualized consultation — rather than a generic protocol pulled from a forum — is the appropriate starting point.

Monitoring Progress and Adjusting Protocols

Because the entire point of a GHRH analog is to move the GH/IGF-1 axis, monitoring is built around that axis:

• Baseline labs: IGF-1 (the practical proxy for average GH exposure), fasting glucose and HbA1c, and often a metabolic and hormone panel before starting.
• Follow-up IGF-1: re-checked during a cycle to keep the value within an age-appropriate physiological range — the goal is optimization, not supraphysiologic elevation.
• Glucose watch: because GH can reduce insulin sensitivity, glucose markers are monitored, especially in anyone with metabolic risk.
• Symptom tracking: sleep, recovery, energy, water retention, and any tingling/carpal-tunnel symptoms guide dose titration.

Dose adjustment is typically downward if IGF-1 runs high or side effects (edema, tingling, glucose creep) appear, and small/incremental if response is muted. Adjustments are made by the prescribing clinician, not by chasing a higher dose independently.

A realistic response timeline

What to expect, and when, helps set expectations and prevents premature dose escalation:

• Weeks 1-2: often improved sleep depth and a subjective sense of recovery; possible mild water retention as the axis adjusts.
• Weeks 3-6: IGF-1 typically settles into its new range; changes in recovery and training capacity may become noticeable.
• Weeks 6-12: body-composition and skin/connective-tissue changes, if they occur, tend to be gradual and are best judged alongside diet, training, and objective measures rather than the scale alone.

Common CJC-1295 Dosing Mistakes to Avoid

Most problems with CJC-1295 are avoidable and stem from a handful of recurring errors. This section is educational — the fix for all of them is a supervised protocol.

Confusing the DAC and no-DAC forms

The single most dangerous mistake is applying no-DAC daily frequency to the DAC form (or vice versa). Dosing 1-2 mg of the DAC form daily — as if it were the no-DAC amount — would stack a multi-day peptide on itself and drive IGF-1 far too high. Always confirm which form you have before dosing.

Dosing above the saturation point

Because the pituitary GH response to a GHRH pulse plateaus near ~100 mcg (the “1 mcg/kg” convention), doubling a no-DAC dose does not double GH output — it mostly adds cost and side-effect risk. More frequent, correctly sized doses beat one oversized dose.

Eating too close to the injection

Injecting the no-DAC form right after a carb- or fat-containing meal blunts the very GH pulse you are trying to create, because elevated insulin and free fatty acids suppress GH release. The fasted-window rule is not optional fine print — it materially changes the result.

Skipping baseline and follow-up labs

Without IGF-1 and glucose monitoring there is no way to know whether the dose is effective, excessive, or affecting metabolism. Flying blind on a hormone-axis therapy is how people end up with supraphysiologic IGF-1 and its associated risks.

Poor reconstitution and storage technique

Shaking the vial, squirting water directly onto the pellet, using unpreserved water in a multi-dose vial, or leaving the reconstituted solution at room temperature all degrade the peptide. A perfectly calculated dose of degraded peptide does nothing.

Is CJC-1295 FDA-Approved? Legal & Regulatory Status (2026)

No. As of July 2026, CJC-1295 (in either the DAC or no-DAC form) is not approved by the FDA for any medical indication. It has no approved consumer or prescription product and is not sold as a dietary supplement.

• Compounding status: The regulatory environment for compounded peptides tightened after the FDA’s late-2024 advisory review of several peptides, and CJC-1295’s availability through compounding pharmacies has become more restricted in 2026. Because these determinations change, patients should rely on their physician and a licensed compounding pharmacy for the current, accurate status rather than on vendor claims.
• Not “research use only” for you: Products marketed as “research chemicals” or “not for human consumption” are not a lawful workaround for self-use. This guide does not endorse obtaining CJC-1295 from such sources.
• Anti-doping (WADA/USADA): CJC-1295 is prohibited at all times — in and out of competition — under the WADA Prohibited List as a growth-hormone-releasing factor (category S2, growth hormone secretagogues/GHRFs). Any competitive or tested athlete must treat it as banned.

By contrast, sermorelin has an FDA-approval history and can be compounded with a prescription, and tesamorelin is FDA-approved for a specific indication (HIV-associated visceral fat). CJC-1295 sits outside both of those categories. BHRC does not sell raw or research peptide; where a peptide is offered, it is only within a physician-supervised, compounded, individualized program.

Conclusion

CJC-1295 is a two-in-one topic: a long-acting DAC form dosed at 1-2 mg once or twice weekly, and a short-acting no-DAC form (Mod GRF 1-29) dosed at 100-300 mcg one to three times daily, almost always with ipamorelin and almost always before bed. The DAC version buys weekly convenience at the cost of a flatter GH pattern; the no-DAC version preserves the body’s natural pulse but demands daily, well-timed dosing. Human evidence — chiefly the Teichman 2006 DAC trials and the Ionescu-Frohman pulsatility study — is encouraging but small and short, and the peptide is not FDA-approved and is banned in sport. That combination of promise and open questions is exactly why CJC-1295 belongs in a physician-directed program with baseline and follow-up labs, not in a self-administered experiment.

Schedule a Peptide Therapy Consultation with Beverly Hills Rejuvenation Center →

Frequently Asked Questions About CJC-1295 Dosing

What is the standard CJC-1295 dosage?

It depends on the form. CJC-1295 with DAC is typically 1-2 mg once or twice weekly (its half-life is 6-8 days). CJC-1295 without DAC — Modified GRF 1-29 — is typically 100-300 mcg, one to three times daily, because its half-life is only about 30 minutes. The two are dosed completely differently and are not interchangeable.

What’s the difference between CJC-1295 with DAC and without DAC?

“DAC” is a Drug Affinity Complex — a linker that lets the peptide bind albumin in your blood, extending its half-life from ~30 minutes to ~6-8 days. That’s why the DAC form is dosed weekly and produces a sustained GH/IGF-1 elevation, while the no-DAC form (Mod GRF 1-29) is dosed daily and produces short, natural GH pulses.

How do I convert a CJC-1295 dose to insulin-syringe units?

Divide the vial’s total micrograms by the milliliters of bacteriostatic water you added to get the concentration (mcg/mL). On a U-100 syringe, 100 units = 1 mL. Example: a 5 mg vial in 2 mL = 2,500 mcg/mL, so a 100 mcg dose = 0.04 mL = 4 units. Always recalculate when a new vial is mixed at a different volume, and confirm your program’s prescribed dose.

When should I take CJC-1295?

No-DAC/Mod GRF 1-29 is best taken right before bed on an empty stomach, so its short pulse stacks on the body’s natural nighttime GH surge; optional fasted morning or pre-workout doses catch extra windows. The DAC form’s timing matters far less because it stays active for days — a consistent weekly (or twice-weekly) injection is the norm.

Why is CJC-1295 usually combined with ipamorelin?

They work on two different pathways. CJC-1295 (a GHRH analog) increases how much GH is available to release, while ipamorelin (a ghrelin-receptor secretagogue) triggers a clean pulse and eases the somatostatin “brake.” Together they produce a larger, more physiological GH pulse than either alone, which is why the no-DAC + ipamorelin stack is the most common clinical use.

How long is a CJC-1295 cycle?

Typical cycles run 8-12 weeks followed by a planned break of about 4+ weeks (some daily no-DAC users run a 5-days-on/2-days-off weekly pattern). Cycling and lab-guided breaks help gauge response and avoid pushing IGF-1 too high for too long. There’s no established lifetime duration — it’s an individualized, physician-directed decision.

Is CJC-1295 FDA-approved?

No. As of July 2026 CJC-1295 is not FDA-approved in either form, is not a supplement, and its compounding availability has become more restricted since the FDA’s 2024 peptide review. It is also banned in sport by WADA at all times. Products sold as “research chemicals” are not a lawful path to self-use.

How is CJC-1295 different from sermorelin?

Sermorelin is native GHRH (1-29) with a ~10-20 minute half-life and a naturally pulsatile effect, and it has FDA-approval history and can be compounded with a prescription. CJC-1295 is the same fragment engineered for stability — the no-DAC form gives a slightly longer clean pulse, and the DAC form adds albumin binding for weekly dosing. CJC-1295 is not FDA-approved.

What side effects should I watch for with CJC-1295?

Most common are injection-site reactions, facial flushing, water retention or puffiness, occasional tingling/carpal-tunnel-type symptoms, headache, and drowsiness after a pre-bed dose. The main deeper concern is chronically elevated IGF-1 and its effects on glucose and cell proliferation, which is why IGF-1 and glucose are monitored on a supervised protocol.

Can I reconstitute and dose CJC-1295 myself at home?

This guide explains reconstitution and syringe math so you can understand a prescribed protocol — not so you can source and self-administer peptide. CJC-1295 is not FDA-approved, dosing must be individualized to your labs, and both sourcing quality and IGF-1 monitoring require a physician and a licensed compounding pharmacy. Do not self-treat.

Related Resources / Related Blogs from BHRC

• CJC-1295 / Ipamorelin Dosage Guide: Complete Protocol
• Ipamorelin Dosage Guide (sibling guide — confirm URL is live before publishing)
• CJC-1295 / Ipamorelin Peptide Therapy
• CJC-1295 No-DAC Peptide Therapy
• Tesamorelin Peptide Therapy
• Start Your Journey — Peptide Therapy Consultation

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. DOI: 10.1210/jc.2006-1702. https://doi.org/10.1210/jc.2006-1702
3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. (GHRH 1-29 comparator; identifier not asserted — verify before publication.)
4. World Anti-Doping Agency. The 2026 Prohibited List — Section S2.2 (Growth Hormone, its Fragments and Releasing Factors, incl. GHRH analogs such as CJC-1295). https://www.wada-ama.org/en/prohibited-list
5. Falutz J, et al. Tesamorelin (a stabilized GHRH analog) for HIV-associated visceral adiposity — the FDA-approved GHRH-analog comparator. N Engl J Med. 2007 (and subsequent trials). (Cited as regulatory contrast; verify specific citation before publication.)
6. U.S. Food & Drug Administration. Compounding and the FDA’s evaluation of bulk drug substances / Pharmacy Compounding Advisory Committee materials on peptide substances (2024-2026). https://www.fda.gov/drugs/human-drug-compounding

This educational content does not create a physician-patient relationship and is not a substitute for individualized medical advice. CJC-1295 is not FDA-approved. Any therapy is provided only within a supervised, individualized program after appropriate evaluation. This content has been reviewed by the BHRC clinical team.